$TEVA - Today we can confirm the signal for LONGNot for a suggestion. Longby Samuel12_1980Published 3
$TEVA - Very long above 11.2 (Support 9.75)Holding from deep. Not for a suggestion.Longby Samuel12_1980Published 5
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov Longby AaronXPublished 4
tevai would not long unless longterm trend line breaks with buy pressure. if it breaks maybe it can go to new highsby NolossesGodPublished 113
TEVA - 4/20/2020TEVA - Tenkan sen is about to cross death of Kijun sen is a bad sign. In addition, both lines are about the get into cloud means increased volatility ahead, struggling inside the cloud. TEVA is a sell here.by MS110Published 112
$TEVA - Respect the price 10$, its the support now.Above MA50 and MA200 (with a hope it will stay above it). Next target is 12$. Below 10$, I save the respect to 8.95 with price closing. Not for a suggestion.Longby Samuel12_1980Published 228
TEVA Pharma attempting to break long term trend Moving average currently holding as support Above $10.50 a possible long $12.00 a short term target below long term trendline. Longby RedHotStocksPublished 16
teva cup patternTeva seems to have the cup with handle pattern. The next resistance line is at 13.50 ish, so until then it looks like teva will rise up and then bounce back a little bit to 11/12. It may also be possible that Teva can reach 20 in SeptemberLongby nicitachicitaPublished 7
$TEVA Catches Fresh Momo as Malaria Drugs Get the NodTEVA shares are popping to start off the week as the company gets into the middle of the chloroquine emphasis to battle the COVID-19 outbreak. The longer-term picture is defined by the potential for fresh momentum after successfully holding key support.by GregFolinPublished 6
TEVA building a Cause?This is still a while out (I think) but its been added to the watchlist for sure.Longby AyricPublished 7
Long position in TevaTeva can have more upside than downside at the moment. Longby Konner90Published 5
Teva Pharmaceutical $TEVAIt couldn't' break first fibonacci level and rsi 50. It is going down for double bottom?by TheBullseyePublished 1
TEVA Pharmaceuticals Potentially forming a Falling Wedge BottomIn my experience trendly / volatile stocks have a tendency to have significant long term reversals from wedges and general downtrendline breaks. Extremely interested to see where this goes, if it does end up breaking out bullishly. Company could begin a new bull run, or simply reach target and mean revert.by UnknownUnicorn3844238Updated 3
Juicy After Hours MoveI've been thinking the bottom was near considering Teva is a pharmaceutical company. With the news of Israel shutting down (with exception of grocery/pharmacy) due to the Corona Virus, we may have the catalyst we needed for a reversal. Business will not be effected and opiate settlement will be hard to continue to fight with governments needing all pharma on deck. BUY BUY BUY.Longby lroman90Updated 3
Teva Pharmaceutical Industries Ltd covic-19 Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need. "We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost," said Brendan O’Grady, Teva Executive Vice President, North America Commercial. "Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately." Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month. Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients. Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.Longby BullishchartsPublished 1152
Speculative High-Return Idea - LONG "TEVA"I'm not gonna explain the fundamental data of the company for a long time, but I will say briefly that if you look at the dynamics of changes in the company's data, you can see a stable growth of the EPS indicators and a gradual moving towards a positive P&L. It is also indicative that with the huge fall of markets last week, the company did not “fly down” after the market. In the pharmaceutical sector, which itself is risky for investors, TEVA in recent months has shown good growth and the POTENTIAL for the long-term trend to transition from falling to rising. It has already broken up the resistance line lasting from the highest 2015 year point. However, the idea of this post is no longer in long-term investment in this asset, but in speculative buying. The graph clearly shows the divergence of the asset price lows and its RSI and MACD indicators. According to Fibonacci, the stock adjusted to the desired level. Perhaps the fall to the level of 3703 Israeli Shekels and a rebound, or a rebound will be tomorrow. In any case, it is recommended to wait until the RSI fixes above 30 on the 1-hour chart, and then go into the idea. The way out of the idea is at least 4100 Shekels. Stop loss at your discretion, but 3650 is recommended. If you do not have access to the Israeli market, then do not be discouraged, paper is also listed in America under the same name TEVA P.S. It’s up to you to enter long-term or speculate, I recommend speculating only because I myself am a short-term speculator.Longby Eminence-GrisePublished 3
Cup and HandleThe chart depicts a classic cup and handle formation. Place a stop buy order slightly above the upper trend line of the handle. There is a risk of missing the trade if the price continues to advance and does not pull back. TEVA is still undervalued compared to fair value - they reported positive drug trial data in Japan, and had a nice breakout this week. gl!Longby IQimokucomPublished 6